Investigation of several hypotheses related to the outcome of the Chingelput Bacille Calmette-Guérin (BCG) Trial suggests at least 2 factors that might explain the major scientific puzzle of a protective effect expected of 80% and a protective effect observed of 0% (i.e., equivalent protection for BCG and placebo). One factor that explains some of the low efficacy observed for BCG in this trial is the virtual saturation level of exposure to environmental mycobacteria (EM). Studies in animal models demonstrated that the protection afforded by infection with EM was equivalent to the protection that resulted from BCG vaccination. The second factor, pathogenetic pathway, explains why there was still a high case rate for tuberculosis, even though the population was fully vaccinated by EM. This hypothesis states that tuberculosis in India, as well as in most developing countries, results primarily from exogenous reinfection, a pathway against which BCG (or EM) exerts no protective effect beyond that induced by the first episode of infection with Mycobacterium tuberculosis.
The Chingelput Trial [1, 2] was the largest controlled field trial of BCG to date. Launched by the Indian Council of Medical Research (ICMR) and the World Health Organization (WHO) in the early 1970s, this trial involved 1360,000 persons living in rural villages of 100-1000 persons in the Chingelput District, near Madras in south India. A major objective of the Chingelput Trial was to compare the potency of BCG in an area at sea level, where sensitivity to environmental mycobacteria (EM) was known to be high, with a mountainous area, where sensitivity to EM was known to be low. However, it became necessary for the investigators to revise the objective of the trial to eliminate the area of low sensitivity to EM.
For a given village, on the day of intake into the trial, persons aged у10 years were administered skin tests with PPD-S and PPD-B (intracellularin prepared from Mycobacterium avium-intracellulare) and were x-rayed. Then they were randomly allocated to receive either of 2 BCG vaccines at 1 of 2 doses or placebo. Follow-up at 2.5-year intervals included a chest xray. If the chest film revealed abnormalities compatible with tuberculosis, 2 sputum samples were collected, one immediately and the other overnight. These were sent to Madras for culture and for identification of the species of Mycobacteria. This was the first BCG trial in which the definition of a case of tuberculosis was based on sputum culture.
At the start of the trial, the principal investigator predicted that BCG vaccine would show a protective efficacy of at least 80%. At the fifth 2.5-year follow-up interval, the investigators were stunned to find that the protective potency of 2 of the most widely employed BCG vaccines was identical to that of the group given placebo [1, 2] . Efforts were begun immediately to formulate hypotheses that might explain the unexpected outcome of the trial. These hypotheses (table 1) later became the central focus of the ICMR-WHO Scientific Working Group "Vaccination against Tuberculosis," held in New Delhi in May 1980 [3] . Investigation into the results of the Chingelput Trial began, with an examination of the factors that determine whether a protective effect of BCG is observed (table 2) .
The Danish strain of BCG, 1 of the 2 vaccines used in the trial, showed an efficacy of 78% in the Medical Research Council Trial in the United Kingdom [4] . Twenty years' experience with this strain demonstrated a uniformly high degree of protection in guinea pigs vaccinated intradermally and challenged via the respiratory route with small numbers of virulent tubercle bacilli [5] .
Hart [6] , after examining the work of Palmer and Long [7] , suggested that 2 criteria must be met in order for infection with atypical mycobacteria to fully explain the outcome of any BCG trial. First, the incidence of infection with atypical mycobacteria in the population must be very high. Second, the immunity imparted by this infection must be as good as that obtained with BCG. With respect to Hart's first criterion, skin tests with PPD-B revealed that 95% of the population included in the Chingelput Trial were reactors to EM. With regard to Hart's second criterion, a study was undertaken [8] in which the vaccination treatments included placebo, BCG-Copenhagen, and M. avium-intracellulare, an isolate from the Chingelput trial area shown to be capable of inducing sensitization to PPD-B. The animals were subdivided into groups for challenge via the respiratory route with 1 of 3 strains of Mycobacteria: a highvirulence isolate and a low-virulence isolate were obtained from patients in the trial area and the laboratory strain H37Rv.
Measures of protection included the number of bacilli re- covered from primary lung lesions and primary lesion-free lung lobes and the extent of hematogenous seeding to the spleen. The findings for all 3 measures of protection revealed that (1) both vaccines exhibited the high level of protection normally observed for BCG-Copenhagen and that (2) there was no evidence of an interference between the protective potency of BCG and that of M. avium-intracellulare [9] . These findings indicate that infection with EM provides one explanation for the apparent absence of protective effect in the Chingelput Trial. By contrasting the data observed in the guinea pig model with the outcome of the trial, it is possible to suggest the way that infection with EM influenced the Chingelput Trial (see table 3 ). The findings of the Chingelput Trial suggest that there may have been no true placebo group (table 3 assumes a protection scale of 0%-80%). In the animal model, the observed high level of protective efficacy for the group given BCG was arbitrarily set at 80% on the scale and the level of protection of the placebo group set at 0%. On the basis of the assumption that prior infection with EM would have little influence, it was expected that the Chingelput Trial would also show a strong protective effect of BCG, as evidenced by a conspicuous reduction in the tuberculosis in the vaccinated group compared with that in the placebo group.
However, this expected outcome was not observed, because the case rate in the BCG vaccinated group was not different from that of the placebo group. There are 2 ways to explain this result. One possibility (possibility A in table 3) is that the BCG vaccines used in the trial were not protective (i.e., the 2 vaccination treatment groups lie together on the protection scale at 0%). Evidence against this possibility is prior evidence in humans [4] and animal models [5] that demonstrates that the vaccines induced a uniformly high protective potency. The second way to explain the outcome of no difference in the number of cases in the placebo and BCG groups is listed as possibility B in table 3: both the BCG-vaccinated and the placebo group had the same number of cases but were at the 80% value on the protection scale. The evidence in favor of possibility B stems from the findings presented for the first 30 months of the trial, which showed that the case rate in the 0-to 7-mm PPD-S reactor group was only 20% of the expected number [1, 2] . The discrepancy between expected and observed cases in the 0-to 7-mm reactor group could reflect the vaccinating effect of saturation level exposure to EM. Thus, according to this hypothesis, the trial objective-to determine the efficacy of BCG vaccination in an area of known high sensitivity to EM-was realized. Infection with EM protected as well as BCG. One conclusion drawn from the Chingelput Trial is that the saturation level of exposure to M. avium-intracellulare protected humans to the same extent as the BCG vaccine, thereby eliminating the placebo group essential for demonstrating a protective effect of BCG. This finding is a variance with the data of Rook et al. [9] but is in agreement with the finding of Edwards et al. [8] .
Because the trial data showed a higher than expected number of tuberculosis cases even in a vaccinated population, it is appropriate to consider an additional hypothesis that tuberculosis in the trial area was due to exogenous reinfection, a pathway against which BCG offers no protection beyond that of the first infection with M. tuberculosis [10] .
As a background for considering pathogenetic pathways, figure 1A [11] shows the distribution of primary lesions in 105 individuals. This figure indicates that the primary lesion of tuberculosis can occur anywhere in the lung. In contrast, figure 1B [12] shows the distribution of 205 single cavitary lesions in 205 patients. The vast majority of these single cavitary lesions are in the apical-subapical region of the lungs (i.e., the "vulnerable region") [13] . Evidence indicates that there are 2 pathways by which tubercle bacilli reach the vulnerable region. Endogenous reactivation tuberculosis depends on the survival and reactivation of bacilli in foci seeded via the bacillemia that accompanies the primary infection with virulent tubercle bacilli. Exogenous reinfection tuberculosis is independent of a bacillemia and develops at a site in the lung seeded directly via the airway with either virulent or attenuated tubercle bacilli. ten Dam and Pio [10] suggest that much of the tuberculosis in the developing countries of the world follows the exogenous pathway.
The distinction between these 2 pathways is of great importance, because BCG protects against one pathway and not the other and because of the known differences in the time course of the 2 infectious processes [1, 2] . In endogenous reactivation tuberculosis, the most common form of tuberculosis in developed countries, tubercle bacilli of high virulence are transported to the vulnerable region via the bloodstream. In contrast, in exogenous reinfection tuberculosis, the most common form of tuberculosis in developing countries, tubercle bacilli that may be of reduced virulence are transported to the vulnerable region by repeated exposures via the airway. Mitchison [14] reported that 65% of isolates of tubercle bacilli obtained from patients in the trial area were of reduced virulence for guinea pigs. These findings were confirmed and extended by Prabhakar et al. [15] . It has been suggested that the isolates of low virulence may be successfully seeded to the vulnerable region as a consequence of repeated exposures [16] .
Moreover, evidence indicates that BCG inhibits the bacillemia of endogenous reactivation tuberculosis [17, 18] but appears to have no influence on exogenous reinfection tuberculosis beyond the protection afforded by the initial infection [10] . If ten Dam and Pio are correct [10] that tuberculosis in the developing countries of the world follows the exogenous pathway, then research is needed for the development of vaccines that protect against the exogenous pathway.
Conclusion
Investigation of several hypotheses related to the outcome of the Chingelput BCG Trial suggest at least 2 factors that could explain the major scientific puzzle of a protective effect expected of 80% and a protective effect observed of 0% (i.e., equivalent protective effect for BCG and placebo). One factor that explains some of the low apparent efficacy observed for BCG in this trial is the virtual saturation level of exposure to EM. Infection with EM in the guinea pig model protected as well as BCG; therefore, in effect in the field trial since 95% of the population were reactors to PPD-B, there was no true placebo group. The second factor, pathogenetic pathway, explains why there was still a high case rate for tuberculosis, even though the population was fully vaccinated by EM. This hypothesis states that tuberculosis in India (and most developing countries) results primarily from the exogenous reinfection pathway, against which BCG (or EM) exerts no protective effect beyond that induced by the first infection with M. tuberculosis. Prompted in part by the developing HIV epidemics, several tuberculosis conferences [19] [20] [21] [22] have concluded that control of the world tuberculosis problem must give high priority to the development of new vaccines that protect not only against endogenous reactivation tuberculosis but also those that influence exogenous reinfection tuberculosis, by preventing the reactivation of bacilli in the one-third of the world's population already infected. A corollary to these new vaccine recommendations is that research is needed for the development of a clearer understanding of the endogenous and exogenous pathways to tuberculosis.
